publication date: Feb. 28, 2017

Ovarian Cancer TapImmune Announces Progress in Phase II Trial

TapImmune Inc. said Memorial Sloan Kettering Cancer Center successfully completed the first safety cohort in its phase II ovarian cancer study.

The study is designed to examine the efficacy of the TapImmune lead investigational product candidate, TPIV 200, in combination with AstraZeneca’s investigational checkpoint inhibitor, durvalumab. The phase PP ovarian cancer study is sponsored by MKSCC under the leadership of Jason Konner.

This clinical milestone allows MSKCC to increase the number of patients that can be enrolled and will subsequently increase the study’s enrollment rate. Patients in this study are resistant to platinum chemotherapy and have few treatment options.

Since TPIV 200 and durvalumab have not been used before in combination, the protocol required the start of the study to proceed cautiously for the first four patients. There have been no safety issues to date, and the enrollment is now allowed to proceed at a faster rate.

“This study and the TapImmune-sponsored phase II study in triple negative breast cancer study represent the company’s progress in clinical development of its lead product, TPIV 200,” said Glynn Wilson, chairman and CEO of TapImmune, Inc. “We also recently announced the opening of our second ovarian cancer study with FDA Fast Track designation in platinum-sensitive patients. As we have previously stated, TapImmune has Fast Track designation … Continue reading CCL Feb 2017 – TapImmune Announces Progress in Phase II Trial

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.